TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
TORL BioTherapeutics has raised $96.0M in total funding. The most recent round was Series C. The last funding was announced in October 2025.
TORL BioTherapeutics's investors include RA Capital Management, Goldman Sachs, Perceptive Advisors, Blue Owl, Vertex Ventures HC.
TORL BioTherapeutics is headquartered in Culver City, United States.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
TORL BioTherapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TORL BioTherapeutics — Funding & Investors." VCBacked, October 7, 2025, https://www.vcbacked.co/company/torl-biotherapeutics. Accessed September 23, 2026.
VCBacked. (2025). TORL BioTherapeutics — Funding & Investors. Retrieved September 23, 2026, from https://www.vcbacked.co/company/torl-biotherapeutics
{{cite web |title=TORL BioTherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/torl-biotherapeutics |website=VCBacked |access-date=September 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated